Nonetheless, almost half of the AML patients receiving this drug do not show a response, prompting investigations of combination therapy with pan- or class-I specific HDAC inhibitors [3], or biologicals such as retinoids. The gene discussed is HDAC9; the disease is acute myeloid leukemia.